Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
50
DRUG Quote, Financials, Valuation and Earnings
Last price:
$82.24
Seasonality move
:
-32.54%
Day range:
$81.55 - $88.67
52-week range:
$23.18 - $97.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.85x
Volume:
188K
Avg. volume:
166.2K
1-year change:
104.38%
Market cap:
$639.5M
Revenue:
--
EPS (TTM):
-$1.24
Analysts' Opinion
-
Consensus RatingBright Minds Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $93.21, Bright Minds Biosciences, Inc. has an estimated upside of 13.51% from its current price of $82.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $93.21 representing 100% downside risk from its current price of $82.12.
Fair Value
-
According to the consensus of 6 analysts, Bright Minds Biosciences, Inc. has 13.51% upside to fair value with a price target of $93.21 per share.
DRUG vs. S&P 500
-
Over the past 5 trading days, Bright Minds Biosciences, Inc. has overperformed the S&P 500 by 2.67% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bright Minds Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bright Minds Biosciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bright Minds Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Bright Minds Biosciences, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bright Minds Biosciences, Inc. reported earnings per share of -$0.41.
Enterprise value:
580M
EV / Invested capital:
9.82x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.46x
EV / Free cash flow:
-91.51x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$54.9K
Return On Assets:
-23.91%
Net Income Margin (TTM):
--
Return On Equity:
-24.38%
Return On Invested Capital:
-24.31%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$53.7K | -$53.9K | -$54.9K | -$13.9K | -$12.3K | |
| Operating Income | -$5.5M | -$2.1M | -$10M | -$578.2K | -$4.1M | |
| EBITDA | -$5.4M | -$2M | -$9.9M | -$564.3K | -$4.1M | |
| Diluted EPS | -$1.47 | -$0.51 | -$1.24 | -$0.13 | -$0.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $15.8M | $8.7M | $5M | $4.4M | $60.6M | |
| Total Assets | $15.8M | $8.8M | $5.1M | $4.5M | $60.7M | |
| Current Liabilities | $504.1K | $1.1M | $207.7K | $391.3K | $1.7M | |
| Total Liabilities | $504.1K | $1.1M | $207.7K | $420.6K | $1.7M | |
| Total Equity | $15.3M | $7.7M | $4.9M | $4.1M | $59M | |
| Total Debt | -- | $101.8K | $54.4K | $88.1K | $90.4K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.2M | -$1.4M | -$6.3M | -$342.8K | -$946.3K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $1.6M | $597K | $63.1M | -$15.4K | $24.4M | |
| Free Cash Flow | -$5.2M | -$1.4M | -$6.3M | -$342.8K | -$946.3K | |
DRUG
Sector
Market Cap
$639.5M
$27.8M
Price % of 52-Week High
84.01%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-13.64%
-1.55%
1-Year Price Total Return
104.38%
-17.47%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$85.05
200-day SMA
Buy
Level
$44.02
Bollinger Bands (100)
Buy
Level
43.31 - 71.67
Chaikin Money Flow
Buy
Level
32.5M
20-day SMA
Buy
Level
$80.02
Relative Strength Index (RSI14)
Buy
Level
55.99
ADX Line
Buy
Level
51.46
Williams %R
Neutral
Level
-68.9153
50-day SMA
Buy
Level
$67.56
MACD (12, 26)
Buy
Level
5.48
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
275M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (162.5548)
Buy
CA Score
(Annual)
Level (0.3049)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (7.1105)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, DRUG has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DRUG average analyst price target in the past 3 months is $93.21.
-
Where Will Bright Minds Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bright Minds Biosciences, Inc. share price will rise to $93.21 per share over the next 12 months.
-
What Do Analysts Say About Bright Minds Biosciences, Inc.?
Analysts are divided on their view about Bright Minds Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bright Minds Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $93.21.
-
What Is Bright Minds Biosciences, Inc.'s Price Target?
The price target for Bright Minds Biosciences, Inc. over the next 1-year time period is forecast to be $93.21 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DRUG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bright Minds Biosciences, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DRUG?
You can purchase shares of Bright Minds Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bright Minds Biosciences, Inc. shares.
-
What Is The Bright Minds Biosciences, Inc. Share Price Today?
Bright Minds Biosciences, Inc. was last trading at $82.24 per share. This represents the most recent stock quote for Bright Minds Biosciences, Inc.. Yesterday, Bright Minds Biosciences, Inc. closed at $82.12 per share.
-
How To Buy Bright Minds Biosciences, Inc. Stock Online?
In order to purchase Bright Minds Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DRUG Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DRUG
Sector
P/E ratio
--
23.89x
PEG ratio
-0.46x
-0.01x
P/B ratio
10.85x
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
DRUG
Sector
Revenue growth
--
4.62%
Earnings growth
-230.25%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.72
-$0.21
Profitability
DRUG
Sector
Profitability FY 2025
-$55K
$3.5M
Return on invested capital
-24.31%
-31.77%
Return on assets
-23.91%
-27.96%
Return on equity
-24.38%
-37.63%
Earnings Date
Last Earnings Date
Dec
27
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Mar
28
Balance Sheet
DRUG
Sector
Total cash
$59.6M
$26.3M
Short term investments
--
$25.7M
Total assets
$60.7M
$78M
Long term debt
$90.4K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
